InMode Sets 2020 Stretch Goal To Exceed 2019 Revenue
InMode Sets 2020 Stretch Goal To Exceed 2019 Revenue
Since its IPO in August 2019, InMode’s (Nasdaq: INMD) stock price has risen 60.8 percent vs. the U.S. Medical Equipment index’ rise of just 17.2 percent. InMode commercializes its innovative minimally invasive and non-invasive technologies, including adipose fat tissue remodeling, capitalizing on the global medical aesthetics market which is projected to reach $18.9 billion by 2024.
InMode has managed its business through the Covid-19 pandemic for long-term success and is positioned to meet or exceed 2019’s revenue results, so I’m bullish on the stock over the medium term,” says Donovan Jones, founder of IPO Edge.
